Lapatinib-Capecitabine Versus Capecitabine Alone as Radiosensitizers in RAS Wild-Type Resectable Rectal Cancer, an Adaptive Randomized Phase II Trial (LaRRC Trial): Study Protocol for a Randomized Controlled Trial
Trials - United Kingdom
doi 10.1186/s13063-016-1583-y
Full Text
Open PDFAbstract
Available in full text
Date
September 21, 2016
Authors
Publisher
Springer Science and Business Media LLC